WO1998046270A3 - Molecules presentant une pluralite de groupes fonctionnels actifs - Google Patents

Molecules presentant une pluralite de groupes fonctionnels actifs Download PDF

Info

Publication number
WO1998046270A3
WO1998046270A3 PCT/US1998/007171 US9807171W WO9846270A3 WO 1998046270 A3 WO1998046270 A3 WO 1998046270A3 US 9807171 W US9807171 W US 9807171W WO 9846270 A3 WO9846270 A3 WO 9846270A3
Authority
WO
WIPO (PCT)
Prior art keywords
polyvalent
methods
presenters
presenter
polyvalently
Prior art date
Application number
PCT/US1998/007171
Other languages
English (en)
Other versions
WO1998046270A2 (fr
Inventor
George Whitesides
James B Tananbaum
John Griffin
Mathai Mammen
Original Assignee
Advanced Medicine Inc
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Medicine Inc, Harvard College filed Critical Advanced Medicine Inc
Priority to JP54407498A priority Critical patent/JP2002503223A/ja
Priority to KR1019997009364A priority patent/KR20010006280A/ko
Priority to EP98918079A priority patent/EP0973551A2/fr
Priority to BR9808521-2A priority patent/BR9808521A/pt
Priority to CA002286692A priority patent/CA2286692A1/fr
Priority to AU71069/98A priority patent/AU743028B2/en
Publication of WO1998046270A2 publication Critical patent/WO1998046270A2/fr
Publication of WO1998046270A3 publication Critical patent/WO1998046270A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/00756—Compositions, e.g. coatings, crystals, formulations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des compositions polyvalentes permettant de présenter de façon polyvalente un agent thérapeutique. Ces compositions pharmaceutiques contiennent un agent de présentation polyvalent. Selon une réalisation, l'agent de présentation est formulé comme (Y)-(X-A)n, Y étant un squelette, X une liaison directe ou un lien, A un groupe fonctionnel à fonction de présentation, et n un entier supérieur à 10 choisi de façon que les groupes à fonction de présentation puissent entrer en interaction avec une pluralité de sites cibles de liaison. La composition peut également comporter un vecteur pharmaceutiquement acceptable. Selon une autre réalisation, l'agent de présentation peut constituer lui-même son propre vecteur pharmaceutiquement acceptable. L'invention concerne également le traitement d'affections ou d'états. Ce traitement consiste en l'administration à un sujet d'une pluralité de groupes A de façon que le traitement se produise. Le traitement se produit du fait de l'interaction d'un agent de présentation polyvalent avec une pluralité de sites cibles de liaison B. Sous d'autres aspects, l'invention concerne, d'une part des agents de présentation polyvalents emballés avec un mode d'emploi destiné aux traitements considérés, et d'autre part des procédés de conception, d'agents de présentation polyvalent convenant particulièrement dans le cadre des procédés et traitements de l'invention. Les agents de présentation polyvalents de l'invention assurent une liaison spécifique, ce qui est relativement avantageux. En outre, ces agents de présentation polyvalents permettent des interactions positives et négatives.
PCT/US1998/007171 1997-04-11 1998-04-09 Molecules presentant une pluralite de groupes fonctionnels actifs WO1998046270A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP54407498A JP2002503223A (ja) 1997-04-11 1998-04-09 複数の活性分子を供与する分子
KR1019997009364A KR20010006280A (ko) 1997-04-11 1998-04-09 다수개의 활성 잔기를 제공하는 분자
EP98918079A EP0973551A2 (fr) 1997-04-11 1998-04-09 Molecules presentant une pluralite de groupes fonctionnels actifs
BR9808521-2A BR9808521A (pt) 1997-04-11 1998-04-09 Moléculas que apresentam um grande número de partes ativas.
CA002286692A CA2286692A1 (fr) 1997-04-11 1998-04-09 Molecules presentant une pluralite de groupes fonctionnels actifs
AU71069/98A AU743028B2 (en) 1997-04-11 1998-04-09 Molecules presenting a multitude of active moieties

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4378197P 1997-04-11 1997-04-11
US60/043,781 1997-04-11
US4382697P 1997-04-14 1997-04-14
US60/043,826 1997-04-14

Publications (2)

Publication Number Publication Date
WO1998046270A2 WO1998046270A2 (fr) 1998-10-22
WO1998046270A3 true WO1998046270A3 (fr) 1999-01-07

Family

ID=26720814

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/007171 WO1998046270A2 (fr) 1997-04-11 1998-04-09 Molecules presentant une pluralite de groupes fonctionnels actifs

Country Status (8)

Country Link
EP (1) EP0973551A2 (fr)
JP (1) JP2002503223A (fr)
KR (1) KR20010006280A (fr)
CN (1) CN1269013A (fr)
AU (1) AU743028B2 (fr)
BR (1) BR9808521A (fr)
CA (1) CA2286692A1 (fr)
WO (1) WO1998046270A2 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2330611A1 (fr) 1998-05-22 1999-12-02 The Board Of Trustees Of The Leland Stanford Junior University Molecules bifonctionnelles et therapies basees sur celles-ci
JP3468149B2 (ja) * 1999-02-19 2003-11-17 松下電器産業株式会社 微細物体の操作装置および操作方法
EP1177029B1 (fr) * 1999-05-10 2004-03-17 Glaxo Group Limited Station de travail haute capacite de criblage de formes cristallines et son utilisation
US6887842B1 (en) 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
WO2001035978A1 (fr) 1999-11-19 2001-05-25 The Board Of Trustees Of The Leland Stanford Junior University Molecules bifonctionnelles ciblees et therapies basees sur celles-ci
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
KR100543171B1 (ko) * 2002-05-31 2006-01-20 한국과학기술원 분자수준에서 배향성을 조절하면서 항체 단분자막을 제조하는 방법
CA2583666A1 (fr) * 2004-10-13 2006-04-27 Ilypsa, Inc. Preparations pharmaceutiques comprenant un oligosaccharide complexant les toxines et une particule polymere
CN101325963B (zh) 2005-10-08 2016-01-27 博泰迪亚制药公司 用于眼部病症的补体抑制素和其类似物
ES2545775T3 (es) 2007-02-05 2015-09-15 Apellis Pharmaceuticals, Inc. Análogos de compstatina para uso en el tratamiento de afecciones inflamatorias del sistema respiratorio
EP2139524A1 (fr) * 2007-03-23 2010-01-06 The Governors of the University of Alberta Polymères hétérobifonctionnels multivalents et leurs procédés d'utilisation
EP2192923A2 (fr) * 2007-08-27 2010-06-09 Massachusetts Institute of Technology Inhibiteurs du virus de la grippe couplés à un polymère bifonctionnel
CN107050422B (zh) 2011-05-11 2021-11-09 阿佩利斯制药公司 细胞反应性的、长效的或靶向的坎普他汀类似物及其用途
MX363606B (es) 2011-06-22 2019-03-28 Apellis Pharmaceuticals Inc Uso de inhibidores del complemento en trastornos crónicos.
SI3660033T1 (sl) 2012-11-15 2021-09-30 Apellis Pharmaceuticals, Inc. Analogi kompstatina z dolgotrajnim delovanjem in sorodni sestavki in postopki
WO2014134297A1 (fr) * 2013-02-28 2014-09-04 The University Of Southern Mississippi Liaison covalente de bactériophages à des surfaces polymères
RU2770099C2 (ru) 2015-10-07 2022-04-14 Апеллис Фармасьютикалс, Инк. Схемы введения
KR20210084552A (ko) 2018-10-29 2021-07-07 위스콘신 얼럼나이 리서어치 화운데이션 향상된 암 면역요법을 위한 면역관문 억제제와 복합체화된 덴드리틱 폴리머
US11564995B2 (en) 2018-10-29 2023-01-31 Wisconsin Alumni Research Foundation Peptide-nanoparticle conjugates
KR20220092557A (ko) 2019-10-29 2022-07-01 위스콘신 얼럼나이 리서어치 화운데이션 펩티드-나노입자 접합체

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010023A1 (fr) * 1989-03-01 1990-09-07 Biocarb Ab Copolymeres a base d'acrylglucides et de methacrylglucides ainsi que leur fabrication
WO1998014215A2 (fr) * 1996-10-02 1998-04-09 Syntesome Gesellschaft Für Med. Biochemie M.B.H. Glyconconjugues comme inhibiteurs d'adherence cellulaire virale

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990010023A1 (fr) * 1989-03-01 1990-09-07 Biocarb Ab Copolymeres a base d'acrylglucides et de methacrylglucides ainsi que leur fabrication
WO1998014215A2 (fr) * 1996-10-02 1998-04-09 Syntesome Gesellschaft Für Med. Biochemie M.B.H. Glyconconjugues comme inhibiteurs d'adherence cellulaire virale

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
BERNKOP-SCHNURCH A ET AL: "Development and in vitro evaluation of systems to protect peptide drugs from aminopeptidase N.", PHARM RES, FEB 1997, VOL. 14, NO. 2, PAGE(S) 181-5, XP002081687 *
CHOI S -K ET AL: "GENERATION AND IN SITU EVALUATION OF LIBRARIES OF POLY(ACRYLIC ACID) PRESENTING SIALOSIDES AS SIDE CHAINS AS POLYVALENT INHIBITORS OF INFLUENZA-MEDIATED HEMAGGLUTINATION", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 119, no. 18, 7 May 1997 (1997-05-07), pages 4103 - 4111, XP002068481 *
CHOI S -K ET AL: "MONOMERIC INHIBITORS OF INFLUENZA NEURAMINIDASE ENHANCE THE HEMAGGLUTINATION INHIBITION ACTIVITIES OF POLYACRYLAMIDES PRESENTING MULTIPLE C-SIALOSIDE GROUPS", CHEMISTRY AND BIOLOGY, vol. 3, no. 2, 1996, pages 97 - 104, XP000650760 *
GAMBARYAN A S ET AL: "SPECIFICATION OF RECEPTOR-BINDING PHENOTYPES OF INFLUENZA VIRUS ISOLATES FROM DIFFERENT HOSTS USING SYNTHETIC SIALYLGLYCOPOLYMERS: NON-EGG-ADAPTED HUMAN H1 AND H3 INFLUENZA A AND INFLUENZA B VIRUSES SHARE A COMMON HIGH BINDING AFFINITY FOR 6'-SIALYL(N-ACETYLLACTOSAMINE)", VIROLOGY, vol. 232, no. 2, 9 June 1997 (1997-06-09), pages 345 - 350, XP002068479 *
GAMIAN A ET AL: "Inhibition of influenza A virus hemagglutinin and induction of interferon by synthetic sialylated glycoconjugates.", CAN J MICROBIOL, MAR 1991, VOL. 37, NO. 3, PAGE(S) 233-7, XP002081684 *
ITOH M ET AL: "SUPPRESSION OF INFLUENZA VIRUS INFECTION BY AN N-THIOACETYLNEURAMINIC ACID ACRYLAMIDE COPOLYMER RESISTANT TO NEURAMINIDASE", VIROLOGY, vol. 212, 1995, pages 340 - 347, XP002036922 *
LEES W.J. ET AL: "Polyacrylamides bearing pendant alpha-sialoside groups strongly inhibit agglutination of erythrocytes by influenza A virus: Multivalency and steric stabilization of particulate biological systems", J. MED. CHEM., 1994, VOL. 37, NO. 20, PAGE(S) 3419-3433, XP002082176 *
MATROSOVICH M.N. ET AL: "Synthetic polymeric sialoside inhibitors of influenza virus receptor-binding activity", FEBS LETT., 1990, VOL. 272, NO. 1-2, PAGES 209-212, XP002081685 *
RYE PD ET AL: "Monoclonal antibody LU-BCRU-G7 against a breast tumour-associated glycoprotein recognizes the disaccharide Gal beta 1-3GlcNAc.", GLYCOBIOLOGY, JUN 1995, VOL. 5, NO. 4, PAGE(S) 385-9, XP002081686 *
TADAO NAKAYA: "POLYMERIC GLYCOLIPID ANALOGUES POLYMETHACRYLATES CONTAINING GLUCOSE MOIETIES ATTACHED TO THE POLYMER BACKBONES VIA N-ALKYL CHAINS OF VARIOUS LENGTH", MAKROMOLEKULARE CHEMIE, RAPID COMMUNICATIONS, vol. 14, no. 2, 1 February 1993 (1993-02-01), pages 77 - 83, XP000334494 *
TOKOVENKO I P ET AL: "INHIBITION OF MYCOPLASMA PNEUMONIAE ADHESION IN THE FETUINIC TEST SYSTEM BY SYNTHETIC ANALOGUES AND POLYMEIC FORMS OF NEURAMINIC ACIDS", MIKROBIOLOGICESKIJ ZURNAL, vol. 56, no. 1, 1994, pages 3 - 9, XP002026326 *
VLASOVA EV ET AL: "[Selectin receptors. 5. Monoclonal antibodies to the synthetic antigens SiaLe(a) and SiaLe(x)]", BIOORG KHIM, MAY 1996, VOL. 22, NO. 5, PAGE(S) 358-65, XP002081688 *
ZEMLIANUKHINA TV ET AL: "[Selectin receptors. 2. Synthesis of HSO3-3'Le(a)--a sulfated ligand of the cell adhesion molecule, E-selectin (letter)]", BIOORG KHIM, MAY 1994, VOL. 20, NO. 5, PAGE(S) 556-9, XP002081689 *

Also Published As

Publication number Publication date
JP2002503223A (ja) 2002-01-29
CN1269013A (zh) 2000-10-04
KR20010006280A (ko) 2001-01-26
CA2286692A1 (fr) 1998-10-22
BR9808521A (pt) 2000-05-23
AU743028B2 (en) 2002-01-17
WO1998046270A2 (fr) 1998-10-22
EP0973551A2 (fr) 2000-01-26
AU7106998A (en) 1998-11-11

Similar Documents

Publication Publication Date Title
WO1998046270A3 (fr) Molecules presentant une pluralite de groupes fonctionnels actifs
PL336704A1 (en) Multivalent vaccine containing a mixed carrier
EP0954340A4 (fr) Immunotherapie-cible associee contre le cancer
HUP0300421A2 (hu) Kezelési eljárás ligand-immunogén konjugátumok felhasználásával
EA200501810A1 (ru) Композиция конъюгированного лекарственного средства
CA2366702A1 (fr) Compositions et procedes d'administration amelioree d'agents therapeutiques hydrophobes ionisables
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
AU6185398A (en) Charged lipids and uses for the same
EP1537861A3 (fr) Utilisation de composés aminothiols pour le traitement de la xerostomie induite par des agents thérapeutiques ou la radiation
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
AU2003273413A1 (en) Pharmaceutically active oligosaccharide conjugates
TR200100841T2 (tr) Antibiyotiklerin kullanımı
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
EP0722324A4 (fr) Composition pharmaceutique s'utilisant pour une therapie de renforcement immunitaire
HK1025737A1 (en) Treatment of multiple sclerosis through ingestion of copolymer-1
AU2412695A (en) Taxane class derivative based pharmaceutical compositions
MXPA02011247A (es) Quimioterapia de combinacion.
IL147149A0 (en) Novel diphenyl-piperidine derivate
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
TW198685B (fr)
NZ240926A (en) Radioactively labelled modified oligonucleotide labelled with a therapeutic isotope and compositions thereof
BR0017329A (pt) Formulção farmacêutica de um medicamento, uso de melatonina na fabricação de um medicamento, e, método para prevenção ou tratamento de sintomas de discinesia tardia em um paciente usanto tal medicamento
WO2020240502A3 (fr) Polythérapie
AU3991899A (en) Verotoxin b subunit for immunization
WO1999064050A8 (fr) Medicaments a canal potassium et leur utilisation

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98804085.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1998918079

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2286692

Country of ref document: CA

Ref document number: 2286692

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1019997009364

Country of ref document: KR

Ref document number: PA/a/1999/009309

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1998 544074

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 71069/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 500458

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1998918079

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997009364

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 71069/98

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1998918079

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019997009364

Country of ref document: KR